Blinatumomab and Inotuzumab Ozogamicin Sequential Use for the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia: A Real-Life Campus All Study.
Nicola Stefano FracchiollaAlessandra IurloCristina PapayannidisAntonella VitaleSabina ChiarettiMario AnnunziataFabio GiglioPrassede SalutariFabio ForghieriDavide LazzarottoMonia LunghiAnnalisa ImovilliBarbara ScappiniMassimiliano BonifacioMichelina DargenioCarmela GurrieriElisabetta TodiscoMarzia DefinaMaria Ilaria Del PrincipePatrizia ZappasodiMarco CerranoLidia SantoroElena TagliaferriEnrico BarozziPasquale De RobertoMarta CanziElisa BuzzattiChiara SartorFrancesco PassamontiRobin FoàAntonio CurtiPublished in: Cancers (2023)
In our series of R/R B-ALL, Blina and InO treatment demonstrate efficacy for subsequent relapses in terms of MRD response, OS and DFS, and as a bridge to allo-HSCT.